SCHEMBL6310099

SCHEMBL6310099

CCOC(=O)c1cccn2c1nc1c(C#N)c(C)c(-c3ccccc3)c(Cl)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 11/20 0.43
L3MBTL1 Q9Y468 6/20 0.43
AKT1 P31749 1/20 0.43
AKT2 P31751 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
NPSR1 Q6W5P4 3/20 0.41
HTT P42858 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TDP1 Q9NUW8 4/20 0.39
LMNA P02545 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6310096 0.75 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2ALOX15HSD17B10ALDH1A1
SCHEMBL9088814 0.75 MEN1 (0.58) KDM4ESMN1; SMN2ALOX15HSD17B10ALDH1A1
SCHEMBL6310367 0.75 HTT (0.43) KDM4ESMN1; SMN2HSD17B10ALDH1A1L3MBTL1
SCHEMBL15289337 0.74 KDM4E (0.48) KDM4ESMN1; SMN2ALOX15HSD17B10ALDH1A1
SCHEMBL13035437 0.69 CYP1A2 (0.80) SMN1; SMN2ALOX15ALDH1A1AKT1AKT2
SCHEMBL6318124 0.68 ALDH1A1 (0.43) KDM4ESMN1; SMN2HSD17B10ALDH1A1L3MBTL1
SCHEMBL6311601 0.68 ALDH1A1 (0.41) KDM4ESMN1; SMN2ALDH1A1L3MBTL1MEN1
SCHEMBL6311836 0.68 GRM2 (0.41) KDM4ESMN1; SMN2HSD17B10ALDH1A1L3MBTL1
SCHEMBL9090657 0.68 SMN1; SMN2 (0.59) KDM4ESMN1; SMN2ALOX15HSD17B10ALDH1A1
SCHEMBL3295021 0.67 ALDH1A1 (0.48) KDM4ESMN1; SMN2ALOX15HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 KDM4E 3360/4885SMN1; SMN2 2642/4885ALOX15 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.